1 Min Read
Oct 26 (Reuters) - Atara Biotherapeutics Inc
* Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230 for treatment of congenital cytomegalovirus (CMV) infection Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.